The Zenas Technologies Difference

Established in 1996 by Dr. William Crumb, a pioneer in QT prolongation
investigation, Zenas offered ion channel assays recorded from native human cardiac myocytes and from stably expressing hERG cells well before any other CRO or Regulatory requirements. Zenas is the first to develop a methodology for screening compounds for hERG liability under physiologic conditions, with the results presented in a physiologically meaningful manner.

The Zenas collaborative approach pursues innovation and welcomes customization. We do more than present comprehensive data packages, we also provide in-depth, expert analysis. Our goal is to conserve your time, money and compound while investing in your customer satisfaction.


“At Zenas Technologies, we are always seeking innovative ways to advance scientific research and help our clients with their discovery, efficacy and
safety drug development programs.”
Dr. William Crumb, Founder